Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas

Blood

Volumn 94, Issue 5, 1999, Pages 1773-1781

  Baur, Audrey S ^a   Shaw, Phil ^a   Burri, Nathalie ^a   Delacrétaz, Françoise ^a   Bosman, Fred T ^a   Chaubert, Pascal ^a  

^a UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; PROTEIN P15; PROTEIN P16; RESTRICTION ENDONUCLEASE;

ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; CPG ISLAND; EXON; GENE INACTIVATION; GENE MAPPING; GENE SILENCING; GENOME; HUMAN; HUMAN TISSUE; LYMPHOCYTE TRANSFORMATION; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL LYMPHOMA;

EID: 0033199104     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.5.1773.417a12_1773_1781     Document Type: Article

References (64)

1. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817, 1993
2. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69:1237, 1992
3. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387:296, 1997
4. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80, 1992
5. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725, 1998
6. Hebert J, Cayuela JM, Berkeley J, Sigaux F: Candidate tumor-suppressor genes MTS1 (p16 INK4A) and MTS2 (p15 INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 84:4038, 1994
7. Hangaishi A, Ogawa S, Imamura N, Miyawaki S, Miura Y, Uike N, Shimazaki C, Emi N, Takeyama K, Hirosawa S, Kamada N, Kobayashi Y, Takemoto Y, Kitani T, Toyama K, Ohtake S, Yazaki Y, Ueda R, Hirai H: Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/ CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood 87:4949, 1996
8. Maestro R, Gloghini A, Doglioni C, Gasparotto D, Vukosavljevic T, De Re V, Laurino L, Carbone A, Boiocchi M: MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas. Blood 85:3239, 1995
9. Watanabe T, Ichikawa A, Saito H, Hotta T: Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymph 21:391, 1996
10. Kawamata N, Miller C, Levy V, Shintaku IP, Koeffler HP, Said JW: mdm-2 oncogene expression in non-Hodgkin's lymphomas. Diagn Mol Pathol 5:33, 1996
11. Villuendas R, Pezzella F, Gatter K, Algara P, Sanchez-Beato M, Martinez P, Martinez JC, Munoz K, Garcia P, Sanchez L, Kocialkowsky S, Campo E, Orradre JL, Piris MA: p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MSM2-, p21-immunophenotype associated with missence p53 mutations. J Pathol 181:51, 1997
12. Capoulade C, Bressac de Paillerets B, Lefrere I, Ronsin M, Feunteun J, Tursz T, Wiels J: Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 16:1603, 1998
13. Sanchez E, Chacon I, Plaza MM, Munoz E, Cruz MA, Martinez B, Lopez L, Martinez-Montero JC, Orradre JL, Saez AI, Garcia JF, Piris MA: Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 16:1931, 1998
14. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704, 1993
15. Serrano M, Lee HW, Chin L, Cordon-Cardo C, Beach D, Depinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27, 1996
16. Cordon-Cardo C: Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147:545, 1995
17. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686, 1995
18. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA: Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531, 1995
19. Herman JG, Merlo A, Mao LI, Lapidus RG, Issa JPJ, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525, 1995
20. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4α tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993, 1995
21. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A: Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 55:2988, 1995
22. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D: A novel p16INK4A transcript. Cancer Res 55:2995, 1995
23. Robertson KD, Jones PA: The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 18:6457, 1998
24. ARF. Cell 91:649, 1997
25. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713, 1998
26. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257, 1994
27. INK4B1. Cancer Res 56:722, 1996
28. Fizzotti M, Cimino G, Pisegna S, Alimena G, Quartarone C, Mandelli F, Pelicci PG, Lo Coco F: Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 85:2685, 1995
29. INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 55:1436, 1995
30. INK4 genes in hematologic malignancies. Leuk Lymph 23:235, 1996
31. Siebert R, Willers CP, Schramm A, Fossa A, Gana Dresen IM, Uppenkamp M, Nowrousian MR, Seeber S, Opalka B: Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukemia cell lines. Br J Haematol 91:350, 1995
32. Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MAR, De Lord C, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E, Oscier DG, Karpas A, Lenoir GM, Smith SD, Millar JL, Catovsky D, Dyer MJS: Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 85:893, 1995
33. Dreyling MH, Bohlander SK, Le Beau MM, Olopade OI: Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood 86:1931, 1995
34. Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K, Kamada N, Ohtake S, Uike N, Shimazaki C, Toyama K, Hirano M, Mizoguchi H, Kobayashi Y, Furusawa S, Saito M, Emi N, Yazaki Y, Ueda R, Hirai H: Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 86:1548, 1995
35. Siebert R, Willers CP, Opalka B: Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma. Leuk Lymph 23:505, 1996
36. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler HP: Homozygous deletions of the p15(MTS2) and p16 (CDKN2/ MTS1) genes in adult T-cell leukemia. Blood 85:2699, 1995
37. Yamada Y, Hatta Y, Murata K, Sugawara K, Ikeda S, Mine M, Maeda T, Hirakata Y, Kamihira S, Tsukasaki K, Ogawa S, Hirai H, Koeffler HP, Tomonaga M: Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol 15:1778, 1997
38. Sill H, Goldman JM, Cross NCP: Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85:2013, 1995
39. ink4A) gene in primary B-cell lymphomas. Blood 86:2724, 1995
40. Neumeister P, Hoefler G, Beham-Schmid C, Schmidt H, Apfelbeck U, Schaider H, Linkesch W, Sill H: Deletion analysis of the p16 tumor suppressor gene in gastrointestinal mucosa-associated lymphoid tissue lymphomas. Gastroenterology 112:1871, 1997
41. Koduru PRK, Zariwala M, Soni M, Gong JZ, Xiong Y, Broome JD: Deletion of cyclin-dependent kinase 4 inhibitor genes p15 and p16 in non-Hodgkin's lymphoma. Blood 86:2900, 1995
42. INK4B in non-Hodgkin's lymphomas. Blood 86:1434, 1995
43. INK4C genes in multiple myeloma. Br J Haematol 96:98, 1997
44. Dreyling MH, Bulliger L, Ott G, Stilgenbauer S, Müller-Hermelink HK, Bentz M, Hiddemann W, Döhner H: Alterations of the cyclin D1/p16-pRb pathway in mantle cell lymphoma. Cancer Res 57:4608, 1997
45. Drexler HG: Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12:845, 1998
46. Elenitoba-Johnson KSJ, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M: Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 91:4677, 1998
47. Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 89:272, 1997
48. Fernandez-Piqueras J, Santos J, Pérez de Castro I, Meléndez B, Martinez B, Robledo M, Rivas C, Benitez J: Frequent allelic losses of 9p21 markers and low indidence of mutations at p16(CDKN2) gene in non-Hodgkin's lymphomas of B-cell lineage. Cancer Genet Cytogenet 98:63, 1997
49. Martinez-Delgado B, Fernandez-Piqueras J, Garcia MJ, Arranz E, Gallego J, Rivas C, Robledo M, Benitez J: Hypermethylation of a 5′ CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia 11:425, 1997
50. Martinez-Delgado B, Robledo M, Arranz E, Osorio A, Garcia MJ, Echezarreta G, Rivas C, Benitez J: Hypermethylation of p15/ink4b/ MTS2 gene is differentially implicated among non-Hodgkin's lymphomas. Leukemia 12:937, 1998
51. INK4A gene in multiple myeloma. Br J Haematol 101:558, 1998
52. INK4A characterize the major types of hematological malignancies. Cancer Res 57:837, 1997
53. Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, Wiman KG: p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 91:1680, 1998
54. Ng MHL, Chung YF, Lo KW, Wickham NWR, Lee JCK, Huang DP: Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89:2500, 1997
55. Harris NL, Jaffe ES, Sein H, Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peteers C, Falini B, Gatter K, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri S, Piris MA, Ralfkiaer E, Warnke R: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
56. Stansfeld AG, Diebold J, Kapanci Y, Noël H, Rilke F, Kelenyi G, Sundstrom C, Lennert K, Van-Unnik JAM, Mioduszewska O, Wright DH: Updated Kiel classification of non-Hodgkin's lymphoma. Lancet 1:292, 1988
57. INK4 (MTS1) gene inactivation in testicular germ cell tumors. Am J Pathol 151:859, 1997
58. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB: Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821, 1996
59. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 89:1827, 1992
60. Chaubert P, Bautista D, Benhattar J: An improved method for rapid screening of DNA mutations by nonradioactive single-strand conformation polymorphism procedure. BioTechniques 15:586, 1993
61. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156, 1987
62. Bird A: The essentials of DNA methylation (review). Cell 70:5, 1992
63. Nan X, Campoy J, Bird A: MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88:471, 1997
64. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386, 1988